Genomic Answers for Children’s Health Act of 2026

Bill Number

H.R. 7118

Origin Chamber

House

Congress

119th Congress, Session 2

Policy Area

Health

Status

Introduced

Latest Action

2026-01-15: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-06-30T08:07:15Z

AI-Generated Summary

Purpose

The Genomic Answers for Children's Health Act of 2026 aims to ensure that advanced genetic testing—specifically whole genome sequencing (analyzing a person's entire DNA) and whole exome sequencing (analyzing the protein-coding parts of DNA)—is explicitly covered under Medicaid for children suspected of having genetic disorders, rare diseases, or unexplained health conditions. This clarification seeks to improve early diagnosis and treatment access for low-income children by reducing barriers like claim denials or payment bundling.

Key Provisions

• Coverage Mandate: Adds whole genome and whole exome sequencing as a covered Medicaid benefit for children under the early and periodic screening, diagnostic, and treatment (EPSDT) services. It must be ordered by a qualified physician or provider as a first-line test for conditions like congenital anomalies (birth defects), global developmental delays, or intellectual disabilities, whether in inpatient or outpatient settings.
• Definition of Services: Defines "whole genome sequencing and whole exome sequencing" to include DNA analysis from the child or their first-degree biological relatives (e.g., parents or siblings) if it aids diagnosis or treatment. It covers the sequencing process itself, plus any related analysis, interpretation, and reporting.
• Payment Rules: Requires states to pay for these tests separately under Medicaid plans, without bundling them into payments for other services. This prevents under-reimbursement.
• Outreach and Education: Directs the Secretary of Health and Human Services (HHS) to:
• Convene stakeholders (e.g., pediatricians, geneticists, hospitals, rare disease groups, states, and Medicaid managed care organizations) to address implementation challenges, like reducing prior authorization denials.
• Conduct awareness campaigns about EPSDT benefits and genetic testing access.
• Publish a report within two years on state payment amounts, number of children tested, health outcomes, and follow-up services.
• Independent Review: Requires the Government Accountability Office (GAO) to submit a report within two years assessing implementation, including feedback on access barriers, care changes, prior authorization impacts, workforce issues for genetic counselors, and reimbursement alignment with market costs. The GAO must recommend improvements to HHS.
• Effective Date: Applies starting January 1, 2027.

Significant Changes to Existing Law

• Amends Section 1905(r) of the Social Security Act (which covers EPSDT services) by inserting a new paragraph explicitly listing whole genome and exome sequencing as covered, and adding a definition subsection (kk). This redesignates an existing paragraph for clarity.
• Updates Section 1902(a) to add a new requirement (paragraph 90) mandating separate payments for these tests, which was not previously specified. This addresses ambiguities in current Medicaid rules that may have led to inconsistent coverage or denials for genetic testing.

Potential Impacts

• On Government Agencies: HHS must lead outreach, stakeholder meetings, and reporting, increasing administrative workload but promoting uniform implementation across states. States will need to update Medicaid plans and payment systems, potentially raising short-term costs but enabling better tracking of health outcomes.
• On Citizens: Low-income children with suspected genetic conditions gain clearer access to cutting-edge testing, which could lead to faster diagnoses, tailored treatments, and improved long-term health. Families may face fewer delays from insurance hurdles, though rural or underserved areas might still encounter provider shortages.
• On International Relations: No direct impact, as this is a domestic health policy focused on U.S. Medicaid.

Main Stakeholders Affected

• Children and Families: Primarily Medicaid-eligible children (under 21) with rare diseases, genetic disorders, or developmental issues, and their families, who benefit from expanded diagnostic access.
• Healthcare Providers: Pediatricians, geneticists, genetic counselors, children's hospitals, and labs, who can order and perform tests with assured reimbursement, though they may need training on new protocols.
• Government and Payers: HHS, state Medicaid agencies, and managed care organizations, responsible for implementation, payments, and compliance.
• Advocacy Groups: Organizations for rare diseases, pediatric care, and Medicaid beneficiaries, involved in outreach and feedback to shape best practices.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens Medicaid's role in preventive and diagnostic care by clarifying coverage, potentially reducing litigation over claim denials under EPSDT rules. It promotes equity in access to emerging technologies without mandating private insurer changes.
• Constitutional: No apparent challenges; aligns with Congress's authority to regulate federal spending programs like Medicaid and promote general welfare through health services for vulnerable populations.
• Political: Bipartisan sponsorship (from Democrats and Republicans) highlights broad support for pediatric health innovation. It could influence future debates on genetic privacy (though not addressed here) or Medicaid expansions, emphasizing cost-effective early interventions to lower long-term healthcare expenses.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Peters, Scott H. [D-CA-50]

Cosponsors (22)

Rep. Bilirakis, Gus M. [R-FL-12], Rep. Veasey, Marc A. [D-TX-33], Rep. Balderson, Troy [R-OH-12], Rep. Mullin, Kevin [D-CA-15], Rep. Carey, Mike [R-OH-15], Rep. Houlahan, Chrissy [D-PA-6], Rep. Salazar, Maria Elvira [R-FL-27], Rep. Auchincloss, Jake [D-MA-4], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Trahan, Lori [D-MA-3], Rep. Lee, Laurel M. [R-FL-15], Rep. McBride, Sarah [D-DE-At Large], Rep. Kean, Thomas H. [R-NJ-7], Rep. Schrier, Kim [D-WA-8], Rep. Miller, Carol D. [R-WV-1], Rep. Matsui, Doris O. [D-CA-7], Rep. Begich, Nicholas J. [R-AK-At Large], Rep. Landsman, Greg [D-OH-1], Rep. Barrett, Tom [R-MI-7], Rep. Tonko, Paul [D-NY-20], Rep. Bacon, Don [R-NE-2], Rep. Pocan, Mark [D-WI-2]

Recent Actions

• 2026-01-15: Referred to the House Committee on Energy and Commerce.
• 2026-01-15: Introduced in House
• 2026-01-15: Introduced in House

Bill Versions

• Genomic Answers for Children’s Health Act of 2026 — issued 2026-01-15 — PDF (7 pages)